ArticleJournal of visualized experiments : JoVE2015
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.
Article in Journal of visualized experiments : JoVE, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Detangling knots: the intricate roles of G-quadruplexes in herpesvirus replication.Journal of virology · 2026Review
- Sialic acid-anchored haemagglutinin stalk neutralizing antibody M-SiaB enhances protection against highly pathogenic influenza H5N1/Texas/2024.Nature communications · 2026Article
- VP1-141 is a determinant of a Vero cell-adapted Coxsackievirus A10 for vaccine development.PLoS neglected tropical diseases · 2026Article
- Gellan Gum/Alginate Films Containing BiogenicMolecules (Basel, Switzerland) · 2026Article
- Decoding of Inconsistent Biological Data: A Critical Step toward Enhanced AI Predictivity in Drug Discovery.ACS pharmacology & translational science · 2026Article
- Carbon dots: A promising tool for viral infection treatment.Materials today. Bio · 2025Review
- Sialic acids as attachment factors in mosquitoes mediating Japanese encephalitis virus infection.Journal of virology · 2024Article
- Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells.International journal of molecular sciences · 2022Article
- The Broad-Spectrum Antiviral Potential of the Amphibian Peptide AR-23.International journal of molecular sciences · 2022Article
- Antiviral Activity of the Rhamnolipids Mixture from the Antarctic BacteriumPharmaceutics · 2021Article
- Article
- The Methanolic Extract ofViruses · 2021Article
- Article
- Ursolic Acid and Its Nanoparticles Are Potentiators of Oncolytic Measles Virotherapy against Breast Cancer Cells.Cancers · 2021Article
- A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells.Computational and structural biotechnology journal · 2021Article
- Immune Modulation to Improve Survival of Viral Pneumonia in Mice.American journal of respiratory cell and molecular biology · 2020Article
- Antiviral Potential of Sea Urchin Aminated Spinochromes against Herpes Simplex Virus Type 1.Marine drugs · 2020Article
- Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.Journal of virology · 2020Article
- The Examination of Viral Characteristics of HIV-1 CRF07_BC and Its Potential Interaction with Extracellular Galectin-3.Pathogens (Basel, Switzerland) · 2020Article
- Prohibitin 1/2 mediates Dengue-3 entry into human neuroblastoma (SH-SY5Y) and microglia (CHME-3) cells.Journal of biomedical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-based systems are useful for discovering antiviral agents. Dissecting the viral life cycle, particularly the early entry stages, allows a mechanistic approach to identify and evaluate antiviral agents that target specific steps of the viral entry. In this report, the methods of examining viral inactivation, viral attachment, and viral entry/fusion as antiviral assays for such purposes are described, using hepatitis C virus as a model. These assays should be useful for discovering novel antagonists/inhibitors to early viral entry and help expand the scope of candidate antiviral agents for further drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.